870 Hermosa Drive
Sunnyvale, CA 94085
Elixir Medical Corp.
Elixir Medical Corp. aims to address the shortcomings of current drug-eluting stents, such as late stent thrombosis, dual antiplatelet therapy duration and better efficacy in more complex disease. Elixir's technology innovations include what it describes as the thinnest durable biocompatible polymer coating, an ultra-thin biodegradable polymer coating and a fully biodegradable drug eluting stent.
More from R&D
More from Scrip
• By
The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.
• By
The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.
• By
ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.